Vico Therapeutics B.V, a clinical-stage genetic medicines company focusing on the development of novel therapies for severe neurological illnesses, has secured €65.8 million ($70.7 million) in Series B financing to advance lead clinical programs, Seroba announced on Monday, June 24, 2024.
Co-founded by Luc Dochez and Josh Mandel-Brehm, the startup’s latest financing round was spearheaded by Seroba, a Dublin-headquartered life sciences venture capital firm, and a European venture capital firm, Kurma Partners.
Seroba led a consortium of companies in the second closing of Vico Therapeutic’s Series B funding round, raising an additional €11.5 million ($12.4 million), with a significant contribution from Kurma Growth Opportunities.
The entire Series B financing round was supported by both new and existing partners such as Ackermans & van Haaren (AvH), EQT Life Sciences, Droia Ventures, Eurazeo, Polaris Partners, Pureos Bioventures, and Kurma Biofund, raising a total of €65.8 million ($70.7 million).
Vico Therapeutics latest funding round is a show of investors’ confidence in the company’s technology and efforts in developing life-changing treatments for severe neurological illnesses, including polyQ diseases, such as Huntington’s and SCA.
Vico Therapeutics Novel Medicine
Vico’s lead program VO659 is undergoing Phase 1/2a clinical study to validate its effectiveness in the treatment of severe neurodegenerative diseases such as Huntington’s and spinocerebellar ataxia types 3 and 1 disease, which, so far, have no disease-modifying therapies.
According to Catello Somma, Partner at Seroba, the new capital infusion will help Vico Therapeutics to grow its portfolio of novel therapies and bolster its clinical trial programs to deliver long-awaited life-enhancing medicines to patients needing them.
